852p 2.0 0.2%
Last Trade - 25/11/20
| Market Cap | £415.1m |
| Enterprise Value | £407.0m |
| Revenue | £73.5m |
| Position in Universe | 592nd / 1803 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 21.2 | 30.2 | 39.2 | 47.6 | 54.1 | 68.3 | 84.8 | 96.8 | +26.4% | ||
| -45.3 | +48.4 | -63.4 | +62.4 | +13.8 | ||||||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2020
|
31st Dec 2021
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Ergomed plc is a provider of drug development services to the pharmaceutical industry. The Company operates through two segments: clinical research services (CRS), and drug safety and medical information services (DS&MI). It provides a range of clinical trial planning, management and monitoring services. It is focused on oncology, neurology and immunology, and the development of orphan drugs. It has two businesses: Services Business and Co-Development Business. The Services Business is a clinical research business providing services to the pharmaceutical and biotechnology industry. The Co-Development Business is a portfolio of partnerships with pharmaceutical and biotechnology companies, providing its drug development services in exchange for a carried interest in any revenues attributable to the drug asset, including out licensing milestones, as well as sales of the product. It provides clinical development, trial management and pharmacovigilance services to over 100 clients.
| Last Annual | December 31st, 2019 |
| Last Interim | June 30th, 2020 |
| Incorporated | September 29, 2000 |
| Public Since | July 15, 2014 |
| No. of Shareholders: | n/a |
| No. of Employees: | 775 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | FTSE Aim All Share , FTSE Aim 100 , |
| Exchange | London Stock Exchange (AIM) |
| Shares in Issue | 48,717,776 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
| Address | 1 Occam Court Occam Road, GUILDFORD, GU2 7HJ, United Kingdom |
| Web | http://www.ergomedplc.com/ |
| Phone | +44 1483 503205 |
| Contact | () |
| Auditors | KPMG |
As of 25/11/20, shares in Ergomed are trading at 852p, giving the company a market capitalisation of £415.1m. This share price information is delayed by 15 minutes.
Shares in Ergomed are currently trading at 852p and the price has moved by 0.135k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Ergomed price has moved by 0.165k% over the past year.
Of the analysts with advisory recommendations for Ergomed, there are there are currently 1 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Ergomed is Strong Buy. You can view the full broker recommendation list by unlocking its StockReport.
Ergomed is scheduled to issue upcoming financial results on the following dates:
Ergomed does not currently pay a dividend.
Ergomed does not currently pay a dividend.
Ergomed does not currently pay a dividend.
To buy shares in Ergomed you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Ergomed are currently trading at 852p, giving the company a market capitalisation of £415.1m.
Here are the trading details for Ergomed:
Based on an overall assessment of its quality, value and momentum, Ergomed is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Ergomed are currently priced at 852p. At that level they are trading at 29.11% discount to the analyst consensus target price of 1,201.86.
Analysts covering Ergomed currently have a consensus Earnings Per Share (EPS) forecast of 0.2385 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Ergomed. Over the past six months, the relative strength of its shares against the market has been 0.107k%. At the current price of 852p, shares in Ergomed are trading at 53.57% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Ergomed PE ratio based on its reported earnings over the past 12 months is 54.77. The shares are currently trading at 852p.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Ergomed's management team is headed by:
Here are the top five shareholders of Ergomed based on the size of their shareholding:
